Engineered High-Affinity Human T Cell Receptors - EP3071594A1

The European Patent Office published application EP3071594A1 for engineered high-affinity human T cell receptors. The application claims priority to TCR engineering technology with applications in cancer treatment (A61P 35/00). The designated states include all EU member states plus Albania, Switzerland, Norway, Turkey, and other European countries.

For pharmaceutical and biotechnology companies engaged in cell therapy or immunotherapy research, this publication establishes prior art for T cell receptor engineering. Companies developing similar TCR-based therapies should conduct freedom-to-operate analyses and monitor the prosecution of this application for potential licensing requirements or design-around opportunities.